Scleroderma Queensland
  • Home
  • About Us
    • Members' Stories
  • Become a Member
  • Donations
  • FUNDRAISING
  • News
  • EVENTS
  • Group Meetings
  • Contact Us

APT-101 Lowers Fibrosis, Inflammation in Mouse Model

16/8/2022

 
Picture
The investigational oral therapy APT-101 was well tolerated and reduced fibrosis, or scarring, in a mouse model of systemic sclerosis (SSc), according to a recent presentation from the therapy’s developer, Apie Therapeutics.
Apie is developing APT-101 to treat interstitial lung disease (ILD), a term that encompasses a group of disorders marked by significant fibrosis and inflammation of the lungs. Patients with SSc often develop ILD as their disease progresses.
According to Apie, the company is on track to file an application with the U.S. Food and Drug Administration (FDA) to begin a clinical testing program for SSc patients, including those with ILD.

Continue reading here.


Comments are closed.

    Author

    Scleroderma Queensland Support Group

    Archives

    January 2023
    December 2022
    November 2022
    October 2022
    September 2022
    August 2022
    July 2022
    June 2022
    May 2022
    April 2022
    March 2022
    February 2022
    February 2021
    December 2020
    November 2020
    October 2020
    September 2020
    August 2020
    March 2020

    Categories

    All
    Announcements
    Community
    Members Stories
    Research
    Resources
    Scleroderma
    Support
    Support Group Meetings
    Useful Links

Scleroderma ​Association of Queensland

​About Us | Members' Stories | Group Meetings | Become a Member
Donate now
Phone 0468 801 021  Email info@scleroderma.org.au
Postal Address PO Box 316, Salisbury Qld 4107
©Scleroderma Association of Queensland. ​All rights reserved. Website by Grey and Grey. 
  • Home
  • About Us
    • Members' Stories
  • Become a Member
  • Donations
  • FUNDRAISING
  • News
  • EVENTS
  • Group Meetings
  • Contact Us